

REMARKS

Formal Matters

In the specification, with the exception of Figures 2, 12 and the sequence listing, the previous amendment to the paragraphs correct minor typographical errors. Formal drawings and a revised sequence listing (equivalent to that which was submitted for the parent application, USSN 09/716,028) are also submitted with the present preliminary amendment.

Figures 2 and 12 are amended from the submission included in the original filing of the grandparent application U.S.S.N. 09/109,207. The revised Figures 2 and 12 correct an error recited in the light chain sequences of the antibodies E26 and E27, while the revised sequence listing corrects the errors appearing in SEQ ID NOS:8, 9, 15 and 17 of the grandparent application.

Figure 12 purports to identify the full length light chain and heavy chain sequences for E25, E26 and E27, while Figure 2 is a comparison between E25, E26, E27 and E426. the sequences purporting to be the E426, E26 and E27 light chain sequences in Figures 12 and Figure 2 contain an error is at light chain residue 37, which should have a leucine in place of the methionine.

However, Figures 13 and 15 illustrate the sequences unmodified from the original filing, which illustrate the Fab fragments of E26 and E27, as well as Figure 15, which describes the F(ab')₂ fragment possess equivalent residues over the common sequences, one of ordinary skill would recognize that a typographical error is present in the light chain sequences of Figures 2 and 12, as well as the corresponding sequences in the sequence listing of SEQ ID NOS:8, 9, 15 and 17. The correct sequence of E426 is also indicated in Figures 10A-F, in which a leucine residue appear at light chain residue 37. The correct residue (*i.e.*, leucine at light chain residue 37 instead of methionine) is also encoded the DNA sequence of SEQ ID NO:1.

Claims 48-65 remain in this application, having been added herewith. No new matter is added by these amendments.

Support for the newly added claims appears at least as indicated below:

Claim 48:

-Support for treating an IgE-mediated disorder appears at least at page 3, lines 24-25, page 8, lines 7-8.

Claims 49-65:

-Support for examples of IgE-mediated disorders and example allergens appears at least at page 1, lines 36-40; page 14, lines 14-19.

Priority

As mentioned in the section amending the cross-reference to related applications, Applicants claim priority under 35 U.S.C. § 120 to (i) U.S.S.N. 09/716,028, filed November 17, 2000, (ii) U.S.S.N. 09/109,207, filed June 30, 1998, filed June 30, 1998 (now U.S.P. 6,172,213) and under 35 U.S.C. § 119 to U.S.S.N. 60/051,554 filed July 2, 1997.

SUMMARY

New claims 48-65 are pending in the application.

If in the opinion of the Examiner, a **telephone conference** would expedite the prosecution of the subject application, the Examiner is **strongly encouraged** to call the undersigned at the number indicated below.

This response/amendment is submitted with a transmittal letter. In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,
GENENTECH, INC.

Date: March 2, 2004

By: Craig G. Svoboda
Craig G. Svoboda
Reg. No. 39,044
Telephone No. (650) 225-1489